← Leaderboards
Michael Tse-Yin Lu
Massachusetts General Hospital
$4,120,399
Attributed
$8,721,662
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,721,662 · 5
By mechanism
U24$3,868,066 · 2
R01$2,484,226 · 1
R33$1,442,594 · 1
U01$926,776 · 1
Top collaborators
- Heather Jane Ribaudo4 shared
- Akl C Fahed3 shared
- Priscilla Y. Hsue2 shared
- Ahmed A Tawakol2 shared
- Kevin J Anstrom1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Guillermo J. Tearney$42,608,505
- Ralph Weissleder$110,468,710
- Steven Kyle Grinspoon$75,757,679
- Ahmed A Tawakol$9,912,063
- Udo Hoffmann$17,171,978
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsHigh RiskRandomizedCardiovascular DiseasesCardiovascular SystemBlood VesselsMyocardial InfarctionEventCoronary Computed Tomography AngiographyRandomized TrialPersonsPreventParticipantPrimary EndpointCohortLow-Density LipoproteinsCollaborationsInflammationSiteBiological MarkersImageAtherosclerosisBloodX-Ray Computed Tomography
Grant awards (10)
2/2 PREEMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis$952,993
U24 · FY2025 · HL
Coronary plaque changes with statin and colchicine among people with high polygenic risk- a mechanistic pilot study$832,994
R01 · FY2025 · HL
2/2 REPRIEVE Extension for Trial Completion$476,233
U24 · FY2025 · HL · contact PI
2/2 REPRIEVE Extension for Trial Completion$1,195,255
U24 · FY2024 · HL · contact PI
Coronary plaque changes with statin and colchicine among people with high polygenic risk- a mechanistic pilot study$816,786
R01 · FY2024 · HL
2/2 REPRIEVE Extension for Trial Completion$1,243,585
U24 · FY2023 · HL · contact PI
Coronary plaque changes with statin and colchicine among people with high polygenic risk- a mechanistic pilot study$834,446
R01 · FY2023 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$721,297
R33 · FY2022 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$721,297
R33 · FY2021 · HL
REPRIEVE - DCC$926,776
U01 · FY2019 · HL · contact PI